Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia

Background: Standard therapy in patients with severe aplastic anemia (SAA) without available HLA-matched sibling donor is immunosuppressive treatment (IST) including antithymocyte globulin (ATG) plus cyclosporine (CSA). However, the predictive marker of the response following IST is still to be fully elucidated.